Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

This patent family provides Composition of Matter coverage beyond 2042 PALI-1908 is in development to treat patients with active fibro stenotic Crohn's Disease (CD) J.D. Finley, Chief Executive Officer of Palisade commented, "We are pleased to further expand our global patent estate for our PALI-2108 and PALI-1908 programs with this European patent. PALI-2108 continues to demonstrate encouraging data and bolster our confidence in its potential as a next-generation therapeutic option for patients with inflam ...